TY - JOUR
T1 - BU/melphalan and auto-SCT in AML patients in first CR
T2 - a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study
AU - Lemoli, R. M.
AU - D'addio, A.
AU - Marotta, G.
AU - Pezzullo, L.
AU - Zuffa, E.
AU - Montanari, M.
AU - De Vivo, A.
AU - Bonini, A.
AU - Galieni, P.
AU - Carella, A. M.
AU - Guidi, S.
AU - Michieli, M.
AU - Olivieri, A.
AU - Bosi, A.
PY - 2010/4
Y1 - 2010/4
N2 - AML patients (total 129; median age 50 years; range 16-72) in first CR received BU and melphalan (BU/Mel) as conditioning regimen before auto-SCT. In all, 82 patients (63.6%) received PBSCs and 47 patients (36.4%) received BM cells. The distribution of cytogenetic categories was conventionally defined as favorable (15.5%), intermediate (60.1%) and unfavorable (24.3%). With a median follow-up of 31 months, the 8-year projected OS and disease-free survival (DFS) was 62 and 56% for the whole population, respectively. The relapse rate was 46% and the non-relapse mortality was 4.65%. Although PBSC transplantation led to a faster hematological recovery than BM transplantation, in univariate analysis the stem cell source, cytogenetics and different BU formulations did not significantly affect OS and DFS, whereas age and the number of post-remission chemotherapy cycles did have a significant effect on the clinical outcome. Multivariate analysis identified age
AB - AML patients (total 129; median age 50 years; range 16-72) in first CR received BU and melphalan (BU/Mel) as conditioning regimen before auto-SCT. In all, 82 patients (63.6%) received PBSCs and 47 patients (36.4%) received BM cells. The distribution of cytogenetic categories was conventionally defined as favorable (15.5%), intermediate (60.1%) and unfavorable (24.3%). With a median follow-up of 31 months, the 8-year projected OS and disease-free survival (DFS) was 62 and 56% for the whole population, respectively. The relapse rate was 46% and the non-relapse mortality was 4.65%. Although PBSC transplantation led to a faster hematological recovery than BM transplantation, in univariate analysis the stem cell source, cytogenetics and different BU formulations did not significantly affect OS and DFS, whereas age and the number of post-remission chemotherapy cycles did have a significant effect on the clinical outcome. Multivariate analysis identified age
KW - AML
KW - Auto-SCT
KW - Conditioning regimen
KW - CR
UR - http://www.scopus.com/inward/record.url?scp=77950626656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950626656&partnerID=8YFLogxK
U2 - 10.1038/bmt.2009.235
DO - 10.1038/bmt.2009.235
M3 - Article
C2 - 19802019
AN - SCOPUS:77950626656
VL - 45
SP - 640
EP - 646
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 4
ER -